Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Mouth Neoplasms 1

Interventions

pembrolizumab 40Cisplatin 32Radiotherapy 22Cetuximab 22Radiotherapy, Intensity-Modulated 15Docetaxel 12Nivolumab 11Paclitaxel 10Fluorouracil 10Carboplatin 8Radiosurgery 6epacadostat 5Radiation 5spartalizumab 4avelumab 4Surgical Procedures, Operative 4Radiotherapy, Conformal 4Immunoglobulin G 4Biopsy 4ribociclib 3durvalumab 3bempegaldesleukin 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Everolimus 3Erlotinib Hydrochloride 3Disulfides 3Cyclophosphamide 3Albumin-Bound Paclitaxel 3utomilumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Squamous Cell Carcinoma of Head and Neck × tozuleristide × Clear all
NCT05316688 2026-02-25

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

University of Washington

Phase 1/2 Terminated
8 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡